Completing data — refresh the page later to see the latest
82626-01-5CCCN(CCC)C(=O)Cc1c(-c2ccc(Cl)cc2)nc2ccc(Cl)cn12JRTIDHTUMYMPRU-UHFFFAOYSA-NAlpidem is a member of imidazoles.
82626-01-5DTXSID8049046CHEMBL54349CHEBI:135649Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 39 reports by companies from 1 notifications to the ECHA C&L Inventory.
Drug Induced Liver Injury Rank (DILIrank 2.0)
Alpidem
vMost-DILI-concern
8
Withdrawn
DOI:10.1016/j.drudis.2016.02.015
Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.
DescriptionAlpidem is an imidazopyridine antianxiety agent with anticonvulsant properties. It is claimed to be the first non-benzodiazepine anxiolytic to show selectivity for the omega-1 modulatory site of the GABA, receptors. Alpidem is reported to be superior to buspirone and similar to the benzodiazepines, but is significantly better tolerated with lower abuse potential.
UsesA peripheral benzodiazepine GABAA receptor ligand, a new anxiolytic
DefinitionChEBI: Alpidem is a member of imidazoles.